Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
08:30:41 EST Mon 10 Nov 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

News for U:EOLS from 2024-11-11 to 2025-11-10 - 37 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2025-11-05 16:05U:EOLSNews ReleaseEvolus Reports Third Quarter 2025 Financial Results
2025-10-28 08:00U:EOLSNews ReleaseEvolus to Participate in 2025 Stifel Healthcare Conference
2025-10-22 08:00U:EOLSNews ReleaseEvolus to Report Third Quarter Financial Results on November 5, 2025
2025-10-10 16:05U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-09-22 09:03U:EOLSNews ReleaseTop Miami Plastic Surgeon Dr. Benjamin Eskenazi Named Lead Consultant for Evolus' Evolysse(TM) Filler Launch
2025-09-12 17:30U:EOLSNews ReleaseEvolus Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-09-08 08:30U:EOLSNews ReleaseEvolus Announces the Appointment of Tatjana Mitchell as Chief Financial Officer
2025-08-25 08:00U:EOLSNews ReleaseEvolus Announces Positive Data From Pivotal Trial for Evolysse(TM) Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp
2025-08-20 08:00U:EOLSNews ReleaseEvolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse(TM) Sculpt Injectable Hyaluronic Acid Gel Product
2025-08-08 16:05U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-08-05 16:05U:EOLSNews ReleaseEvolus Reports Second Quarter 2025 Financial Results and Provides Business Updates
2025-07-31 08:05U:EOLSNews ReleaseEvolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau(TM) as a Top Performer Among Leading Neurotoxins
2025-07-22 08:05U:EOLSNews ReleaseEvolus to Report Second Quarter Financial Results on August 5, 2025
2025-07-11 16:05U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-07-09 08:00U:EOLSNews ReleaseEvolus Expands Global Footprint with Introduction of Nuceiva(TM) (botulinum toxin type A) in France
2025-06-13 16:05U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-06-10 08:00U:EOLSNews ReleaseEvolysse(TM) Recognized in 2025 Shape Skin Awards
2025-05-27 16:15U:EOLSNews ReleaseEvolus Announces Departure of its Chief Financial Officer
2025-05-22 08:00U:EOLSNews ReleaseEvolus Announces Publication of U.S. Pivotal Study for Evolysse(TM) Form and Evolysse(TM) Smooth Injectable Hyaluronic Acid Gels
2025-05-16 16:05U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-05-07 16:05U:EOLSNews ReleaseEvolus Reports First Quarter 2025 Results
2025-05-05 16:05U:EOLSNews ReleaseEvolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility
2025-04-23 08:00U:EOLSNews ReleaseEvolus to Report First Quarter Financial Results on May 7, 2025
2025-04-18 16:05U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-04-16 08:00U:EOLSNews ReleaseEvolus Announces Commercial Launch of Evolysse(TM)
2025-04-15 08:00U:EOLSNews ReleaseEvolus Launches "Drop the F Word" Campaign in Advance of the Commercial Launch of Evolysse(TM) Injectable Hyaluronic Acid Gels
2025-03-25 08:00U:EOLSNews ReleaseEvolus to Participate in The Needham 24th Annual Virtual Healthcare Conference
2025-03-21 16:05U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-03-04 16:05U:EOLSNews ReleaseEvolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance
2025-02-27 08:00U:EOLSNews ReleaseEvolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
2025-02-20 08:00U:EOLSNews ReleaseEvolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit
2025-02-18 08:00U:EOLSNews ReleaseEvolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025
2025-02-13 13:30U:EOLSNews ReleaseEvolus Announces FDA Approval of Evolysse(TM) Form and Evolysse(TM) Smooth Injectable Hyaluronic Acid Gels
2025-02-07 19:09U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-01-21 08:00U:EOLSNews ReleaseEvolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Company's Guidance
2025-01-17 16:05U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-12-13 16:05U:EOLSNews ReleaseEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)